Tissue factor: (patho)physiology and cellular biology

被引:86
作者
Eilertsen, KE [1 ]
Osterud, B [1 ]
机构
[1] Univ Tromso, Fac Med, Dept Biochem, Med Biol Inst, N-9037 Tromso, Norway
关键词
tissue factor; coagulation; antithrombotic; decryption; thrombosis; hemostasis; monocytes;
D O I
10.1097/00001721-200410000-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The transmembrane glycoprotein tissue factor (TF) is the initiator of the coagulation cascade in vivo. When TF is exposed to blood, it forms a high-affinity complex with the coagulation factors factor VII/activated factor VIIa (FVII/ VIIa), activating factor IX and factor X, and ultimately leading to the formation of an insoluble fibrin clot. TF plays an essential role in hemostasis by restraining hemorrhage after vessel wall injury. An overview of biological and physiological aspects of TF, covering aspects consequential for thrombosis and hemostasis such as TF cell biology and biochemistry, blood-borne (circulating) TF, TF associated with microparticles, TF encryption-decryption, and regulation of TF activity and expression is presented. However, the emerging role of TF in the pathogenesis of diseases such as sepsis, atherosclerosis, certain cancers and diseases characterized by pathological fibrin deposition such as disseminated intravascular coagulation and thrombosis, has directed attention to the development of novel inhibitors of tissue factor for use as antithrombotic drugs. The main advantage of inhibitors of the TF(.)FVIIa pathway is that such inhibitors have the potential of inhibiting the coagulation cascade at its earliest stage. Thus, such therapeutics exert minimal disturbance of systemic hemostasis since they act locally at the site of vascular injury. (C) 2004 Lippincott Williams Wilkins.
引用
收藏
页码:521 / 538
页数:18
相关论文
共 236 条
  • [1] Tissue factor expression and angiogenesis in human prostate carcinoma
    Abdulkadir, SA
    Carvalhal, GF
    Kaleem, Z
    Kisiel, W
    Humphrey, PA
    Catalona, WJ
    Milbrandt, J
    [J]. HUMAN PATHOLOGY, 2000, 31 (04) : 443 - 447
  • [2] Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
    Abraham, E
    Reinhart, K
    Svoboda, P
    Seibert, A
    Olthoff, D
    Dal Nogare, A
    Postier, R
    Hempelmann, G
    Butler, T
    Martin, E
    Zwingelstein, C
    Percell, S
    Shu, V
    Leighton, A
    Creasey, AA
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (11) : 2081 - 2089
  • [3] Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
    Abraham, E
    Reinhart, K
    Opal, S
    Demeyer, I
    Doig, C
    Rodriguez, AL
    Beale, R
    Svoboda, P
    Laterre, PF
    Simon, S
    Light, B
    Spapen, H
    Stone, J
    Seibert, A
    Peckelsen, C
    De Deyne, C
    Postier, R
    Pettilä, V
    Sprung, CL
    Artigas, A
    Percell, SR
    Shu, V
    Zwingelstein, C
    Tobias, J
    Poole, L
    Stolzenbach, JC
    Creasey, AA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 290 (02): : 238 - 247
  • [4] AHERN SM, 1993, J BIOL CHEM, V268, P2154
  • [5] The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
    Amengual, O
    Atsumi, T
    Khamashta, MA
    Hughes, GRV
    [J]. THROMBOSIS AND HAEMOSTASIS, 1998, 79 (02) : 276 - 281
  • [6] DIFFERENTIAL EXPRESSION OF TISSUE FACTOR PROTEIN IN DIRECTIONAL ATHERECTOMY SPECIMENS FROM PATIENTS WITH STABLE AND UNSTABLE CORONARY SYNDROMES
    ANNEX, BH
    DENNING, SM
    CHANNON, KM
    SKETCH, MH
    STACK, RS
    MORRISSEY, JH
    PETERS, KG
    [J]. CIRCULATION, 1995, 91 (03) : 619 - 622
  • [7] Armesilla AL, 1999, MOL CELL BIOL, V19, P2032
  • [8] Effect of locally-applied active site-blocked activated factor VII (ASIS) on experimental arterial thrombosis
    Arnljots, B
    Söderström, T
    Ezban, M
    Hedner, U
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 : S145 - S148
  • [9] Fibrin-rich and platelet-rich thrombus formation on neointima: Recombinant tissue factor pathway inhibitor prevents fibrin formation and neointimal development following repeated balloon injury of rabbit aorta
    Asada, Y
    Hara, S
    Tsuneyoshi, A
    Hatakeyama, K
    Kisanuki, A
    Marutsuka, K
    Sato, Y
    Kamikubo, Y
    Sumiyoshi, A
    [J]. THROMBOSIS AND HAEMOSTASIS, 1998, 80 (03) : 506 - 511
  • [10] ROLE OF TISSUE FACTOR IN DISSEMINATED INTRAVASCULAR COAGULATION
    ASAKURA, H
    KAMIKUBO, Y
    GOTO, A
    SHIRATORI, Y
    YAMAZAKI, M
    JOKAJI, H
    SAITO, M
    UOTANI, C
    KUMABASHIRI, I
    MORISHITA, E
    AOSHIMA, K
    NAKAMURA, S
    MATSUDA, T
    [J]. THROMBOSIS RESEARCH, 1995, 80 (03) : 217 - 224